Trial · NCT02152995
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients Progression Free at 6 Months Following Treatment With Trametinib and I-124 (Cohort A) | At 6 months | % of pts progression free at 6 months | NUMBER | |
| PRIMARY | Progression Free Survival (Cohort A) | At 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Percentage With Objective Response (Complete Response or Partial Response) (Cohort A) | At 6 months | % of pts with confirmed partial response | NUMBER | |
| PRIMARY | Iodine Incorporation in Thyroid Cancer Metastases to a Predicted Lesional Absorbed Radiation Dose Equal to or Exceeding 2,000 cGy With the Administration of =< 300 mCi Radioiodine (RAI) (Cohort B) | Up to 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Adequate Increase in Iodine Corporation (Cohort A) | Up to 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Changes in Thyroglobulin | Baseline to up to 6 months | Data were not collected | ||
| SECONDARY | Number of Participants With Toxicity (Cohort A) | Up to 30 days after completion of treatment | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage With an Objective Response (Complete Response or Partial Response) (Cohort B) | At 6 months | % of pts with confirmed partial response | NUMBER | |
| SECONDARY | Percentage of Patients Alive Without Disease Progression (Cohort B) | At 6 months | % of pts progression free at 6 months | NUMBER | |
| SECONDARY | Change in Thyroglobulin (Cohort B) | Baseline up to 6 months | Data were not collected | ||
| SECONDARY | Number of Participants With Toxicity (Cohort B) | Up to 30 days after completion of treatment | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Expression and Phosphorylation of MAPK Signaling Pathway Proteins | Up to 6 months | Data were not collected | ||
| OTHER_PRE_SPECIFIED | Expression and Phosphorylation of Negative Feedback Loops Connected to the MAPK Pathway (Such as Human Epidermal Growth Factor 3) | Up to 6 months | Data were not collected | ||
| OTHER_PRE_SPECIFIED | Quantitative Levels of Messenger Ribonucleic Acid Transcripts for MAPK Regulated and Thyroid-specific Gene Products | Up to 6 months | Data were not collected | ||
| OTHER_PRE_SPECIFIED | Presence of Other Genetic Alterations | Up to 6 months | Data were not collected |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02152995/outcomes